Back to top
more

Maravai LifeSciences (MRVI)

(Delayed Data from NSDQ)

$7.70 USD

7.70
1,260,217

+0.12 (1.58%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $7.70 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (142 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for MRVI

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Maravai LifeSciences Holdings, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 575 632 551 236 25
Receivables 56 147 118 51 18
Notes Receivable 0 0 0 0 0
Inventories 51 43 52 33 14
Other Current Assets 18 26 20 11 4
Total Current Assets 700 848 740 332 61
Net Property & Equipment 163 53 46 101 94
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 766 808 432 0
Intangibles 547 500 270 402 422
Deposits & Other Assets 78 116 53 4 1
Total Assets 1,487 2,282 1,918 1,271 578
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 11 6 8 8 7
Current Portion Long-Term Debt 5 5 6 6 3
Current Portion Capital Leases 1 0 0 0 0
Accrued Expenses 60 53 35 39 19
Income Taxes Payable 7 42 35 0 0
Other Current Liabilities 3 3 10 78 1
Total Current Liabilities 87 110 94 131 30
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 9 15
Convertible Debt 0 0 0 0 0
Long-Term Debt 519 522 525 529 335
Non-Current Capital Leases 32 0 0 56 53
Other Non-Current Liabilities 59 745 755 392 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 698 1,377 1,373 1,116 433
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 3 3 3 3 184
Capital Surplus 129 138 128 85 0
Retained Earnings 286 405 185 1 -42
Other Equity 373 360 230 66 3
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 790 905 545 155 145
Total Liabilities & Shareholder's Equity 1,487 2,282 1,918 1,271 578
Total Common Equity 790 905 545 155 145
Shares Outstanding 251.30 255.20 255.10 257.60 NA
Book Value Per Share 3.14 3.55 2.14 0.60 0.00

Fiscal Year End for Maravai LifeSciences Holdings, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 575 580 580 628
Receivables NA 56 49 49 57
Notes Receivable NA 0 0 0 0
Inventories NA 51 49 47 55
Other Current Assets NA 18 23 23 26
Total Current Assets NA 700 701 699 766
Net Property & Equipment NA 163 154 142 88
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 774 770 767
Intangibles NA 547 554 561 568
Deposits & Other Assets NA 78 86 93 127
Total Assets NA 1,487 2,268 2,264 2,315
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 11 9 7 5
Current Portion Long-Term Debt NA 5 5 5 5
Current Portion Capital Leases NA 1 1 1 0
Accrued Expenses NA 60 56 50 70
Income Taxes Payable NA 7 4 9 42
Other Current Liabilities NA 3 3 2 2
Total Current Liabilities NA 87 78 75 125
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 7 9 9
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 519 520 520 521
Non-Current Capital Leases NA 32 32 32 17
Other Non-Current Liabilities NA 739 731 743
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 698 1,375 1,367 1,415
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 3 3 3 3
Capital Surplus NA 129 125 120 114
Retained Earnings NA 286 392 398 405
Other Equity NA 373 373 377 379
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 790 892 898 901
Total Liabilities & Shareholder's Equity NA 1,487 2,268 2,264 2,315
Total Common Equity 0 790 892 898 901
Shares Outstanding 251.40 251.30 251.00 251.00 250.80
Book Value Per Share 0.00 3.14 3.55 3.58 3.59